-
1. BRF1 ACCELERATES PROSTATE TUMOURIGENESIS AND PERTURBS IMMUNE INFILTRATION
ONCOGENE
2020 ERA MAIN AUTHOR / CONTACT PERSON IN USIM -
2. BRF1 ACCELERATES PROSTATE TUMOURIGENESIS AND PERTURBS IMMUNE INFILTRATION.
ONCOGENE
2019 ERA CO-AUTHOR -
3. VALIDATION OF A FOUR PROTEIN SIGNATURE FOR DETERMINING LYMPH NODE METASTASIS AND SURVIVAL IN ORAL SQUAMOUS CELL CARCINOMA IN 3 MAIN DIAGNOSTIC CENTERS IN MALAYSIA.
ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY AND ORAL RADIOLOGY
2019 SCOPUS CO-AUTHOR -
4. CHEMICAL COMPOSITION AND IN VITRO ANTIMICROBIAL PROPERTIES OF PHYLLANTHUS COLUMNARIS STEM BARK TANNINS AGAINST ORAL PATHOGENS
JOURNAL OF INTERNATIONAL DENTAL AND MEDICAL RESEARCH
2018 WOS CO-AUTHOR -
5. ESTABLISHMENT AND CHARACTERIZATION OF ASIAN ORAL CANCER CELL LINES AS IN VITRO MODELS TO STUDY A DISEASE PREVALENT IN ASIA.
INT J MOL MED.
2007 WOS CO-AUTHOR
ACADEMIC QUALIFICATIONS
- PhD in Cancer Biology (2013)
- Master in Molecular And Genetic Medicine (2005)
- Bachelor in Biomedical Science (2003)
EXPERTISE
- Histology
- Oral Pathology
- Bacteriology
- Cancer
- Molecular Genetics
DR. NOOR AKMAR BINTI NAMPENSYARAH UNIVERSITI DS13 Faculty Fakulti Pergigian Biography A lecturer from Fakulti Pergigian. Holds a Phd in Cancer Biology. Usim Expert: https://expert.usim.edu.my/noorakmar Phone: 03-42892457 E-mail: noorakmar@usim.edu.my |
RESEARCHER
ID
|
-
6. ASSESSMENTS OF SALIVARY BIOMARKERS FOR APPLICATION ON BIOSENSOR IN THE DIAGNOSIS OF PERIODONTAL DISEASE
2019 GERAN PENYELIDIKAN USIM COMPLETED MAIN RESEARCHER -
7. TRANSCRIPTOME ANALYSIS OF ORAL PATHOGENS IN RESPONSE TO TANNIN
2018 GERAN PENYELIDIKAN USIM COMPLETED CO-RESEARCHER -
8. THE ANTIMICROBIAL ACTIVITY OF TANNIN FFROM PHYLLANTUS COLUMNARIS STEM BARK AGAINTS C. ALBIANS, P. GINGIVALIS AND S. MUTANS : AN IN VITRO PATHOGENS.
2017 GERAN PENYELIDIKAN HEADSTART PROGRAM COMPLETED MAIN RESEARCHER -
9. LOSS OF HETEROZYGOSITY (LOH) PROFILING IN ORAL DSYPLASIA LEADING TO ORAL CARCINOMA IN MALAYSIAN PATIENTS
2017 GERAN PENYELIDIKAN USIM COMPLETED MAIN RESEARCHER
Completed: 5 (56%)
Ongoing: 4 (44%)